WiSys Technologies

12 WiSys Technologies in "Diagnostic Assays" or "Information Technology" or "Pharmaceuticals & Vitamin D" or "Research Tools" or "Medical Imaging"

Porous Silicon Nanomembranes for the Rapid Separation of Macromolecules by Size and Shape

WiSys is seeking a strategic partner skilled in the development and manufacturing of membranes used for the separation and/or detection of biologic molecules in solution.  There is additional interest in a partner with the expertise to identify and test novel applications for these nanomembranes.

Monomeric Fluorescent Protein-Ligand Complexes with Strong Fluorescence in the Far-Red Region

WiSys Technology Foundation is seeking a strategic partner with an industry player in the life science tools and reagents industry for the further development and commercialization of its novel monomeric fluorescent protein.

Skin Whitening Agent(s)

WiSys Technology Foundation is currently seeking a strategic industry partner to assist in the further development of its lead compound, A11, and related analogues providing a route to market for their use as novel skin whitening/lightening agents.The competitive advantage of these compounds over existing agents on the market is that they produce long-acting and reversible skin lightening with no toxicity.

High Accuracy Angle Measuring Device for Industrial, Medical, Scientific or Recreational Use

WiSys Technology Foundation is seeking a strategic partner to further develop, manufacture, market, and distribute a high accuracy rotary (angle) encoder. This device has the advantages of high single-reading accuracy (±0.1 arc seconds) and high average reading sensitivity (0.001 arc seconds), low production cost, compact design, and low power consumption. Possible applications include but are not limited to astronomical telescope mounts, land surveillance tools, industrial inspection and calibration, machine tools, medical devices, as well as robotics.

Benzodiazepine Derivatives with Reduced Side Effects

The WiSys Technology Foundation is seeking commercial partners interested in developing anxiolytic and anticonvulsant benzodiazepines that offer little or no side effects.